India-based Dr Reddy's Laboratories has introduced Bupropion HCl extended-release tablets, USP (SR) in 100 mg, 150 mg and 200 mg, a therapeutic equivalent generic version of Wellbutrin SR
(bupropion HCl) Sustained-Release Tablets, in the United States, it was reported yesterday.
Bupropion is the genetic name for the brand Wellbutrin SR
, marketed in the United States by GlaxoSmithKline PLC.
In contrast, the medications mirtazapine (Remeron, Remeron SolTab) and bupropion (Wellbutrin, Wellbutrin SR
, and Wellbutrin XL) have been associated with a lower incidence of sexual side effects.
(The indictment doesn't name the company, but GlaxoSmithKline has confirmed Stevens is now retired from its law department and the drug in question was Wellbutrin SR
.) The indictment alleges Stevens signed and sent letters denying that Glaxo had marketed Wellbutrin for off-label use despite knowing the company paid physicians to promote the drug in talks that included information on unapproved uses.
Stevens allegedly helped the company promote a drug (reportedly the antidepressant Wellbutrin SR
) for unapproved, off-label uses.
Bupropion HCl SR is used in the treatment of major depressive disorder.Bupropion HCl SR tablets, the generic equivalent of GlaxoSmithKline's Wellbutrin SR
, are now available from Actavis in the following strengths: 100mg, 150mg, and 200mg.
unit had received approval to market a generic version of GlaxoSmithKline Plc's Wellbutrin SR
extended release tablets.
Wellbutrin XL once daily maintains bupropion plasma concentrations over 24 hours, helping to eliminate the evening peak in bupropion levels seen with Wellbutrin SR
The strongest evidence is from the recent STAR*D trial, a randomized study that assigned patients in one arm of the study who had no relief from (or did not tolerate) therapy with citalopram (Celexa) to 1 of 3 drugs--sustained-release bupropion (Wellbutrin SR
), sertraline (Zoloft), or extended-release venlafaxine (Effexor XR).
Glaxo, which employs 2,200 people at factories in County Durham and Cumbria, said generic versions of Wellbutrin SR
and Paxil IR had cost it over pounds 1.2bn in lost sales in the first nine months of its financial year.